■ 英語タイトル：Cephalosporin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
	■ 発行会社/調査会社：IMARC ■ 商品コード：IMARC23FB0199 ■ 発行日：2023年2月1日    最新版(2025年又は2026年)版があります。お問い合わせください。 ■ 調査対象地域：グローバル ■ 産業分野：医薬品 ■ ページ数：110 ■ レポート言語：英語 ■ レポート形式：PDF ■ 納品方式：Eメール

The global cephalosporin market size reached US$ 18.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 22.3 Billion by 2028, exhibiting a growth rate (CAGR) of 2.83% during 2023-2028.

Cephalosporins are beta-lactam antibiotics that function in the way similar to penicillin. These broad-spectrum drugs help in treating numerous bacterial infections such as pneumonia, kidney infections, bone infections, meningitis and various sexually transmitted diseases (STDs). There are currently five generations of cephalosporin drugs available in the market with a slight difference in their antibacterial spectrum. These medicines are also differentiated on the basis their administration, excretion, absorption and the duration of the effect of cephalosporin on the body. There are two ways to administer cephalosporin drugs, namely, oral and intravenous (IV). A course of oral cephalosporins is generally used for curing minor infections that are easy to treat such as strep throat. Whereas, IVs are utilized for more severe infections, like meningitis, as these medicines reach tissues quickly than those administered orally.

At present, the rapidly increasing water and air pollution are the primary reasons for the prevalence of infectious diseases across the globe. This has provided a boost to the demand for cephalosporin drugs worldwide. Other than this, various organizations around the world are taking initiatives to improve the development and delivery of antibiotic treatments. One such program is the Global Antibiotic Research and Development Partnership (GARDP), which is a not-for-profit R&D organization formed by the Drugs for Neglected Disease initiative (DNDi) and World Health Organization (WHO). It focusses on the promotion of public-private partnerships for increasing R&D of new antimicrobial diagnostics and agents. The formation of these partnerships is expected to play a significant role in the growth of the cephalosporin market.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global cephalosporin market report, along with forecasts at the global and regional level from 2023-2028. Our report has categorized the market based on generation, route of administration and application.

Breakup by Generation:

First Generation
Second Generation
Third Generation
Fourth Generation
Fifth Generation

Breakup by Route of Administration:

Injection
Oral

Breakup by Application:

Respiratory Tract
Skin Infection
Ear Infection
Urinary Tract Infection
Sexually Transmitted Infection
Others

Breakup by Region:

Asia Pacific
Europe
North America
Middle East and Africa
Latin America

Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Allergan Plc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Lupin Limited, Merck & Co. Inc., Novartis International AG (Sandoz), Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Abbott, Sun Pharmaceutical Industries Limited, etc.

Key Questions Answered in This Report
1. What was the size of the global cephalosporin market in 2022?
2. What is the expected growth rate of the global cephalosporin market during 2023-2028?
3. What are the key factors driving the global cephalosporin market?
4. What has been the impact of COVID-19 on the global cephalosporin market?
5. What is the breakup of the global cephalosporin market based on the generation?
6. What is the breakup of the global cephalosporin market based on the route of administration?
7. What are the key regions in the global cephalosporin market?
8. Who are the key players/companies in the global cephalosporin market?